Safety of and Immune Response to Polyvalent HIV-1 Vaccine in HIV Uninfected Adults
Unknown
This study will evaluate the safety of and immune response to a new HIV vaccine. The vaccine in this trial uses pieces of HIV DNA and HIV proteins. The vaccine itself cannot cause HIV infection or AIDS.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
09/25/2008
Locations: University of Massachusetts School of Medicine, Worcester, Massachusetts
Conditions: HIV Infections
Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia
Completed
The purpose of this study is to evaluate clinical and laboratory safety associated with the administration of GVAX leukemia vaccine and to determine the feasibility of generation of GVAX leukemia vaccine in subjects with acute myelogenous leukemia (AML).
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
12/18/2007
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Acute Myelogenous Leukemia